Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria Brown

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2013
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinomaToni K Choueiri, André P Fay, Robert Gagnon, et al.
BMC Clinical Pathology|July 30, 2014
Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panelAsif Ali, Victoria Brown, Simon Denley, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2013
Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patientsBrooke M Emerling, Cyril H Benes, George Poulogiannis, et al.
EJNMMI Radiopharmacy and Chemistry|October 30, 2019
Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced <sup>225</sup>AcCaterina F Ramogida, Andrew K H Robertson, Una Jermilova, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 20, 2016
Investigating Various Thresholds as Immunohistochemistry Cutoffs for Observer AgreementAsif Ali, Sarah Bell, Alan Bilsland, et al.
BMJ Open|March 30, 2022
Protocol for the Let's Grow randomised controlled trial: examining efficacy, cost-effectiveness and scalability of a m-Health intervention for movement behaviours in toddlersKylie D Hesketh, Katherine L Downing, Barbara C Galland, et al.
Angewandte Chemie (International Ed. in English)|October 1, 2017
An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha TherapyNikki A Thiele, Victoria Brown, James M Kelly, et al.
Journal of Clinical Epidemiology|December 14, 2025
Factors influencing use and choice of Core Outcome Sets and Outcome Measurement Instruments in trials of interventions to prevent childhood obesity: a mixed-methods surveyEibhlín Looney, Moira Duffy, Dimity Dutch, et al.
NPJ Breast Cancer|December 3, 2025
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screenNealia C House, Maxine M Chen, Sima Khazaei, et al.
Cell|November 12, 2013
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumorsBrooke M Emerling, Jonathan B Hurov, George Poulogiannis, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2013
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinomaToni K Choueiri, André P Fay, Robert Gagnon, et al.
BMC Clinical Pathology|July 30, 2014
Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panelAsif Ali, Victoria Brown, Simon Denley, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2013
Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patientsBrooke M Emerling, Cyril H Benes, George Poulogiannis, et al.
EJNMMI Radiopharmacy and Chemistry|October 30, 2019
Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced <sup>225</sup>AcCaterina F Ramogida, Andrew K H Robertson, Una Jermilova, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 20, 2016
Investigating Various Thresholds as Immunohistochemistry Cutoffs for Observer AgreementAsif Ali, Sarah Bell, Alan Bilsland, et al.
BMJ Open|March 30, 2022
Protocol for the Let's Grow randomised controlled trial: examining efficacy, cost-effectiveness and scalability of a m-Health intervention for movement behaviours in toddlersKylie D Hesketh, Katherine L Downing, Barbara C Galland, et al.
Angewandte Chemie (International Ed. in English)|October 1, 2017
An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha TherapyNikki A Thiele, Victoria Brown, James M Kelly, et al.
Journal of Clinical Epidemiology|December 14, 2025
Factors influencing use and choice of Core Outcome Sets and Outcome Measurement Instruments in trials of interventions to prevent childhood obesity: a mixed-methods surveyEibhlín Looney, Moira Duffy, Dimity Dutch, et al.
NPJ Breast Cancer|December 3, 2025
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screenNealia C House, Maxine M Chen, Sima Khazaei, et al.
Cell|November 12, 2013
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumorsBrooke M Emerling, Jonathan B Hurov, George Poulogiannis, et al.
Pageof 7